Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan.

J Cancer · 2022 · PMC9330461 · PMID 35912016

Europe PMC DOI

hedged sentence

0.5640

closest p · 11.3× alpha

0.5640

boldest claim

The sentences

did not reach statistical significancep = 0.564not close (p > 0.1)

The difference in the response rates between the patients with and without osimertinib treatment before atezolizumab therapy did not reach statistical significance (0.0% [0/10] vs. 9.7% [3/31], p = 0.564, by Fisher's exact test).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.